See more : Korea Circuit Co., Ltd. (00781K.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Australis Capital Inc. (AUSAF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Australis Capital Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Harmoney Corp Limited (HMY.AX) Income Statement Analysis – Financial Results
- Agro Tech Foods Limited (ATFL.NS) Income Statement Analysis – Financial Results
- Zhejiang Hongchang Electrical Technology Co., Ltd. (301008.SZ) Income Statement Analysis – Financial Results
- Denbury Inc. (DEN) Income Statement Analysis – Financial Results
- FireFly Metals Ltd (FFM.AX) Income Statement Analysis – Financial Results
Australis Capital Inc. (AUSAF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ausa-corp.com
About Australis Capital Inc.
Australis Capital Inc. operates as a cannabis company. It undertakes cannabis, as well as horticulture projects in the United States, Canada, Denmark Finland, Iceland, Germany, the Netherlands, Bahrein, the United Arab Emirates, Southeast Asia, and Australia, as well as other jurisdictions. The company is based in Las Vegas, Nevada.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Revenue | 7.57M | 570.59K | 221.48K | 129.76K | 0.00 | 0.00 |
| Cost of Revenue | 3.61M | 1.21M | 221.26K | 2.34K | 0.00 | 0.00 |
| Gross Profit | 3.97M | -635.54K | 222.00 | 127.42K | 0.00 | 0.00 |
| Gross Profit Ratio | 52.39% | -111.38% | 0.10% | 98.20% | 0.00% | 0.00% |
| Research & Development | 0.00 | 119.90 | 19.03 | -28.26 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 13.24M | 13.65M | 4.00M | 1.04K | 5.34K |
| Selling & Marketing | 0.00 | 393.20 | 369.35K | 432.94 | 0.00 | 0.00 |
| SG&A | 23.55M | 13.24M | 14.02M | 4.00M | 1.04K | 5.34K |
| Other Expenses | 1.70M | -8.84M | 1.73M | 1.09M | 1.72K | -33.88K |
| Operating Expenses | 25.25M | 8.84M | 14.62M | 4.01M | 1.04K | 5.50K |
| Cost & Expenses | 28.86M | 10.05M | 14.62M | 4.01M | 1.04K | 5.50K |
| Interest Income | 0.00 | 106.77K | 936.76K | 279.71K | 47.16K | 45.02 |
| Interest Expense | 0.00 | 125.22K | 196.56K | 455.69K | 90.54K | 0.00 |
| Depreciation & Amortization | 1.36M | 10.05M | 13.01M | 588.19K | 71.04K | 68.80K |
| EBITDA | -14.13M | -8.87M | -12.25M | -3.01M | 47.85K | -45.18K |
| EBITDA Ratio | -186.60% | -1,553.86% | -5,532.55% | -2,317.99% | 0.00% | 0.00% |
| Operating Income | -15.49M | -9.48M | -14.40M | -4.29M | -1.04K | -5.34K |
| Operating Income Ratio | -204.57% | -1,661.15% | -6,500.66% | -3,309.51% | 0.00% | 0.00% |
| Total Other Income/Expenses | -25.40M | -5.36M | -8.94M | 1.55M | -41.66K | 1.33K |
| Income Before Tax | -40.89M | -19.39M | -23.34M | -4.17M | -42.70K | -4.00K |
| Income Before Tax Ratio | -540.02% | -3,398.90% | -10,539.07% | -3,214.58% | 0.00% | 0.00% |
| Income Tax Expense | 247.44K | -62.18K | 802.74K | 1.04M | 43.38K | -4.00K |
| Net Income | -40.03M | -20.10M | -23.34M | -4.17M | -42.70K | -37.88K |
| Net Income Ratio | -528.67% | -3,522.40% | -10,539.07% | -3,214.58% | 0.00% | 0.00% |
| EPS | -0.16 | -0.11 | -0.14 | -0.04 | 0.00 | 0.00 |
| EPS Diluted | -0.16 | -0.11 | -0.14 | -0.04 | 0.00 | -37.88K |
| Weighted Avg Shares Out | 247.49M | 177.12M | 162.36M | 94.37M | 119.99M | 0.00 |
| Weighted Avg Shares Out (Dil) | 247.49M | 177.12M | 162.36M | 94.37M | 119.99M | 0.00 |
US stocks mixed at open as traders look for direction
10.25am: Proactive North America headlines: Tartisan Nickel Corp (CSE:TN) (OTCMKTS:TTSRF) (FRA:8TA) poised for geophysical survey at flagship Kenbridge nickel-copper-cobalt project Psyched Wellness Ltd (CSE:PSYC) (OTCQB:PSYCF) (FRA:5U9) says it received 'positive' results from its Maximum Tolerated Dosage study of AME-1 Medexus...
Australis Capital looks ahead to "rapid growth" following two transformative acquisitions; ends 3Q with $7.6M cash
Australis Capital Inc (CSE:AUSA) (OTCMKTS:AUSAF) (FRA:AC4) reported its third quarter 2021 results on Monday evening that saw the company end a transformational period with $7.6 million in cash. Revenue for the quarter came in at $90,000, consisting of consulting fees...
US markets heading north at lunch as Fed chair's comments reassure traders
US markets were heading higher at the midday point as investors watched more testimony from Fed Reserve chair Jerome Powell and basked in optimism over news that the FDA said Johnson & Johnson's coronavirus (COVID-19) vaccine should be granted emergency...
Australis Capital buys 51% stake in cannabis facility design/construction company ALPS
Australis Capital Inc (CSE:AUSA) (OTCMKTS:AUSAF) (FRA:AC4) has reached a definitive agreement to acquire 51% of the issued and outstanding shares of cannabis facility design company ALPS, the company announced Wednesday. Australis will pay between C$13.7 million and nearly C$26 million in...
Australis Capital scaling up its award-winning brands across the US and global cannabis markets
Focused on building companies through early-stage, opportunistic, and diversified investments in cannabis space Spun off from Aurora Cannabis in late 2018 Terry Booth, who helped build Aurora, slated to become CEO of Australis What Australis Capital does: Australis Capital Inc (CSE:AUSA) (OTCMKTS:AUSAF)...
Australis Capital says nearing completion of its acquisitions of ALPS and Green Therapeutics
Australis Capital Inc (CSE:AUSA) (OTCMKTS:AUSAF) said Tuesday it is progressing well towards the completion of its proposed acquisitions of ALPS and Green Therapeutics LLC (GT). Australis is seeking a 51% interest in ALPS and the 100% acquisition of the outstanding membership...
Source: https://incomestatements.info
Category: Stock Reports